Beijing Bayi Space LCD Technology Co., Ltd. Class A

Beijing Bayi Space LCD Technology Co., Ltd. Class A

SSSE:688181
34.60
CNY
+0.77
(+2.28%)
0.63EPS
94.88P/E
8.42BMarket Cap
Oct 28Next Earn
Beijing Bayi Space LCD Technology Co., Ltd. Class A
SSE:688181
(Shanghai Stock Exchange)

Recent

price

34.60

P/E

ratio

94.88

div

yld

0.94%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.45
1.42
0.8
0.9
1.24
1.63
2.63
3.88
4.24
4.81
6.56
7.01
5.99
5.49
6.64
6.86
Revenue per Share
0.09
0.14
0.14
0.13
0.01
0.21
0.61
1.13
1.09
1.26
1.53
1.53
0.8
0.57
0.62
0.66
Basic EPS, GAAP
0.09
-0.57
-0.7
0.08
-0.88
-0.25
-0.83
0.28
0.22
0.66
-0.2
-1.49
-3.14
-0.88
-1.44
- -
Free Cash Flow per Basic Share
0.02
0.03
0.02
0.02
0.04
0.04
0.03
- -
0.72
0.26
0.4
- -
0.27
0.14
0.12
0.33
Dividend per Share
0.46
0.89
1.45
1.56
1.93
2.14
4.16
5.29
11.49
12.5
13.6
14.75
15.4
15.51
15.62
15.49
Book Value per Share
0.46
0.89
0.92
1.04
1.42
1.64
3.77
4.89
11.2
12.21
12.69
13.28
13.79
13.9
14.02
13.9
Tangible Book Value per Share
29
35
68
68
65
81
88
101
102
135
135
133
134
134
131
130
Basic Weighted Avg Shares
41
49
54
61
81
133
231
394
430
649
887
934
799
737
868
894
Sales/Revenue/Turnover
10.21
8.45
14.46
9.76
12.13
14
30.83
36.63
30.89
28.23
25.3
23.29
15.03
12.3
13.15
13.47
Operating Margin (%)
1
1
2
3
4
4
5
19
31
34
41
51
45
51
96
- -
Depreciation Expense
2
5
10
9
1
17
53
114
110
170
207
204
107
77
81
86
Net Income, GAAP
27.82
17.78
13.01
16.09
- -
14.22
14.9
14.51
13.73
15.24
15.91
17.6
19.21
26.39
31.71
28.28
Effective Tax Rate (%)
5.93
9.59
17.79
14.34
1.15
12.68
23.12
29.06
25.62
26.28
23.31
21.82
13.36
10.39
9.34
9.62
Profit Margin (%)
30
50
43
43
70
5
141
222
1,223
1,348
1,226
1,028
520
369
395
437
Working Capital
- -
- -
- -
- -
28
21
- -
- -
- -
1
17
8
93
76
189
252
LT Debt
38
73
119
127
157
175
422
536
1,552
1,688
1,837
1,992
2,085
2,098
2,110
2,090
Total Equity
- -
3.43
4.91
2.58
- -
6.26
16.06
24.69
10.64
10.44
11.53
10.35
4.9
3.3
2.99
3.07
Return on Invested Capital (%)
- -
8.56
9.53
7.1
- -
8.06
16.69
23.79
10.51
10.35
11.63
10.44
5.04
3.51
3.62
3.7
Return on Capital (%)
- -
8.5
10.14
7.09
0.65
10.12
17.89
23.91
10.56
10.52
11.73
10.65
5.26
3.69
3.87
4.15
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
489
435
557
LT Borrowings
189
282
252
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
134
134
134
Market Capitalization
4,346
4,075
8,419

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,345
1,320
1,366
Cash, Cash Equivalents & STI
585
489
498
Accounts Receivable, Net
249
285
212
Inventories
390
402
527
Total Current Liabilities
950
840
930
Payables & Accruals
- -
- -
- -
ST Debt
489
435
557
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.09%
4.63%
0.59%
Free Cash Flow
92.09%
117.92%
58.93%
Net Income, GAAP
203.63%
-10.03%
5.83%
Sales/Revenue/Turnover
30.6%
7.52%
17.72%
Total Cash Common Dividend
26,453.63%
2,181.61%
-18.89%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
180
196
173
189
737
2025
214
201
- -
223
868
2026
245
225
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.23
0.09
0.11
0.57
2025
0.18
0.05
- -
0.27
0.62
2026
0.19
0.15
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.02
0.1
0.02
0.14
2025
0.02
0.03
- -
0.03
0.12
2026
0.02
0.24
- -
- -
- -
Business
Beijing Bayi Space LCD Technology Co., Ltd. is a China-based enterprise primarily engaged in the research, development, manufacture, and distribution of advanced electronic display materials, semiconductor electronic chemicals, and specialty pharmaceutical intermediates. Founded in July 2004 and headquartered in Beijing, China, the company operates across display materials, semiconductor materials, and fine chemical industry segments. The company's core product portfolio comprises high-performance thin-film transistor liquid crystal display (TFT-LCD) materials, including twisted nematic (TN), super-twisted nematic (STN), in-plane switching (IPS), and vertical alignment (VA) mixed liquid crystal formulations; organic light-emitting diode (OLED) materials, including OLED functional intermediates and sublimation precursor compounds; polymer-dispersed liquid crystal (PDLC) smart dimming films and switchable film materials; photosensitive polyimide (PSPI) materials utilized in flexible display alignment and advanced semiconductor packaging; electronic-grade photoresist materials, including semiconductor KrF (248nm) lithography photoresist resins and core polymer monomers; and specialty pharmaceutical chemical materials, including advanced active pharmaceutical ingredients (APIs) and customized chemical intermediates. The company distributes its products across mainland China and international markets, primarily supplying leading flat-panel display manufacturers, including BOE Technology Group, HKC Corporation, TCL China Star Optoelectronics Technology (CSOT), and Tianma Microelectronics, alongside semiconductor fabrication suppliers and pharmaceutical manufacturers. In recent strategic developments, the company has actively expanded beyond display liquid crystals to build a comprehensive electronic materials platform. Through its wholly owned subsidiary Zhejiang Bayi Space Advanced Materials Co., Ltd., the company completed and commissioned a hundred-ton-scale automated KrF photoresist resin production facility in Shangyu, Zhejiang Province. Additionally, the company formed a strategic partnership and introduced Xiamen Hengkun New Material Technology Co., Ltd. as a strategic equity investor in Shanghai Bayi Space Advanced Materials Co., Ltd. to accelerate development and downstream verification of advanced lithography photoresist products. In its specialty chemicals division, the company commenced trial production at its Cangzhou manufacturing base in Hebei Province, completing customer qualification and transitioning advanced psychiatric pharmaceutical intermediates into commercial production.